Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium

Journal of Pathology

Volumn 215, Issue 3, 2008, Pages 263-272

  Lopez Beltran, A ^a,g   Alvarez Kindelan, J ^a   Luque, R J ^b   Blanca, A ^a   Quintero, A ^c   Montironi, R ^d   Cheng, L ^e   Gonzalez Campora, R ^f   Requena, M J ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Jaen University Hospital   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g Universidad de Cordoba   (Spain)

Author keywords

9q32 33; Bladder cancer; Cell cycle; DBC1 locus; FGFR3; LOH; Recurrence; Urothelium

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKERATIN 20; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMOSOME 9Q; CLINICAL ARTICLE; CONTROLLED STUDY; DBC1 GENE; DISEASE FREE SURVIVAL; FEMALE; GENE LOCATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS; WESTERN BLOTTING;

AGED; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 46849099468     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2353     Document Type: Article

References (38)

1. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46:170-176.
2. Sauter G, Mihatsch MJ. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same. J Pathol 1998;185:339-341.
3. Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002;440:3-11.
4. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996;78:870- 875.
5. Lopez-Beltran A, Requena MJ, Luque RJ, Alvarez-Kindelan J, Quintero A, Bianca AM, et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol 2006;209:106-113.
6. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M. Morphological diagnosis of the urothelial neoplasms. J Clin Pathol 2007;61:3-10.
7. Montironi R, Scarpelli M, Lopez-Beltran A, Mazzucchelli R, Alberts D, Ranger-Moore J, et al. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential. Cell Oncol 2007;29:47-58.
8. Catto JW, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario DJ, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 2006;175:2323-2330.
9. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999;154:721-727.
10. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-6519.
11. Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 2003;62:1134-1138.
12. Mazzucchelli R, Barbisan F, Stramazzotti D, Montironi R, Lopez-Beltran A, Scarpelli M. Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. Anal Quant Cytol Histol 2005;27:143-151.
13. Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000;60:4021-4025.
14. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH and FISH analyses. J Pathol 2003;199:50-57.
15. Pycha A, Mian C, Hoftrauer J, Brossner C, Haitel A, Wiener H, et al. Multifocality of transitional cell carcinoma results from genetic instability of entire transitional epithelium. Urology 1999;53:92-97.
16. Steidl C, Simon R, Burger H, Brinkschmidt C, Hertle L, Bocker W, et al. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 2002;198:115-120.
17. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, et al. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005;47:58-63.
18. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006;209:336-343.
19. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999;18:2657-2661.
20. Kimura F, Florl AR, Seifert HH, Louhelainen J, Maas S, Knowles MA, et al. Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 2001;85:1887-1893.
21. Knowles MA. Tumor suppressor loci in bladder cancer. Front Biosci 2007;12:2233-2251.
22. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685-2696.
23. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998;185:345-351.
24. Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 2000;19:6317-6323.
25. Tzai TS, Chen HH, Chan SH, Ho CL, Tsai YS, Cheng HL, et al. Clinical significance of allelotype profiling for urothelial carcinoma. Urology 2003;62:378-384.
26. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, Zwarthoff EC. The random development of LOH on chromosome 9q in superficial bladder cancers. J Pathol 2002;198:352-358.
27. Wada T, Berggren P, Steineck G, Adolfsson J, Wijkstrom H, Norming U, et al. Bladder neoplasms - regions at chromosome 9 with putative tumour suppressor genes. Scand J Urol Nephrol 2003;37:106-111.
28. Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11:4415-4429.
29. Williams SV, Sibley KD, Davies AM, Nishiyama H, Hornigold N, Coulter J, et al. Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. Genes Chromosomes Cancer 2002;34:86-96.
30. Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, et al. Hypermethylation at 9q32-33 tumour suppressor region in age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 2001;20:531-537.
31. Habuchi T, Yoshida O, Knowles MA. A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Hum Mol Genet 1997;6:913-919.
32. Tomlinson D, Baldo O, Harnden P, Knowles M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-98.
33. van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 2007;52:760-768.
34. 1/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 2001;20:2956-2964.
35. Nishiyama H, Takahashi T, Kakehi Y, Habuchi T, Knowles MA. Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer 1999;26:171-175.
36. Knowles MA. Identification of novel bladder tumour suppressor genes. Electrophoresis 1999;20:269-279.
37. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A. Garcia-Escudero A, Pareja Megia MJ, Montironi R, et al. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett 2007;250:292-299.
38. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Luque RJ, Alvarez-Kindelan J, Requena MJ, et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett 2006;242:266-272.